BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Currency in USD	2025
Operating Income	409.48 Million
Income Before Tax	482.48 Million
Income Tax Expense	133.58 Million
Net Income	348.90 Million
Eps	1.82
Epsdiluted	1.80
Weighted Average Shs Out	191.79 Million
Weighted Average Shs Out Dil	197.39 Million
Research And Development Expenses	921.93 Million
Selling General And Administrative Expenses	1.15 Billion
Depreciation And Amortization	79.56 Million
Interest Expense	10.90 Million
Interest Income	74.90 Million
Net Interest Income	64.00 Million
Premiums Earned	N/A
Policyholder Benefits	N/A
Gross Profit	2.50 Billion
Ebitda	489.04 Million
Source	edgar
Ebit	493.38 Million

BioMarin Pharmaceutical Inc. Annual Reports (10-K)